{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:27:41Z","timestamp":1789540061251,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","award":["691"],"award-info":[{"award-number":["691"]}],"id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Can J Public Health"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Despite the widespread use of prescription benzodiazepines, there are few studies examining trends and patterns of benzodiazepine-related toxicity. We describe the epidemiology of benzodiazepine-related toxicity in Ontario, Canada.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a population-based, cross-sectional study of Ontario residents who had an emergency department visit or hospitalization for benzodiazepine-related toxicity between January 1, 2013 and December 31, 2020. We reported annual crude and age-standardized rates of benzodiazepine-related toxicity overall, by age, and by sex. In each year, we characterized the history of benzodiazepine and opioid prescribing among people who experienced benzodiazepine-related toxicity, and reported the percentage of encounters with opioid, alcohol, or stimulant co-involvement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between 2013 and 2020, there were 32,674 benzodiazepine-related toxicity encounters among 25,979 Ontarians. During this period, the crude rate of benzodiazepine-related toxicity declined overall, from 28.0 to 26.1 per 100,000 population (age-standardized rate: 27.8 to 26.4 per 100,000), but increased among young adults aged 19 to 24 (39.9 to 66.6 per 100,000 population). Moreover, by 2020, the percentage of encounters associated with active benzodiazepine prescriptions had declined to 48.9%, while the percentage of encounters that had opioid, stimulant, or alcohol co-involvement rose to 28.8%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Benzodiazepine-related toxicity has declined in Ontario overall, but has increased among youth and young adults. Furthermore, there is growing co-involvement of opioids, stimulants, and alcohol, which may reflect the recent emergence of benzodiazepines in the unregulated drug supply. Multifaceted public health initiatives comprising harm reduction, mental health supports, and promotion of appropriate prescribing are needed to reduce benzodiazepine-related harm.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.17269\/s41997-023-00784-3","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T07:02:09Z","timestamp":1686812529000},"page":"956-966","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The epidemiology of benzodiazepine-related toxicity in Ontario, Canada: a population-based descriptive study"],"prefix":"10.17269","volume":"114","author":[{"given":"Tonya J.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Men","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Shearer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Ebejer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Joosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Quercia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Antoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1468-1965","authenticated-orcid":false,"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Ontario Drug Policy Research Network Citizens\u2019 Panel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"1","key":"784_CR1","doi-asserted-by":"publisher","first-page":"e187399","DOI":"10.1001\/jamanetworkopen.2018.7399","volume":"2","author":"SD Agarwal","year":"2019","unstructured":"Agarwal, S. D., & Landon, B. E. (2019). Patterns in Outpatient Benzodiazepine Prescribing in the United States. JAMA Network Open, 2(1), e187399. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.7399","journal-title":"JAMA Network Open"},{"issue":"4","key":"784_CR2","doi-asserted-by":"publisher","first-page":"E208","DOI":"10.9778\/cmajo.20130076","volume":"2","author":"S Alessi-Severini","year":"2014","unstructured":"Alessi-Severini, S., Bolton, J. M., Enns, M. W., Dahl, M., Collins, D. M., Chateau, D., & Sareen, J. (2014). Use of benzodiazepines and related drugs in Manitoba: A population-based study. CMAJ Open, 2(4), E208-216. https:\/\/doi.org\/10.9778\/cmajo.20130076","journal-title":"CMAJ Open"},{"key":"784_CR3","doi-asserted-by":"publisher","first-page":"100138","DOI":"10.1016\/j.fsisyn.2021.100138","volume":"3","author":"K Bollinger","year":"2021","unstructured":"Bollinger, K., Weimer, B., Heller, D., Bynum, N., Grabenauer, M., Pressley, D., & Smiley-McDonald, H. (2021). Benzodiazepines reported in NFLIS-Drug, 2015 to 2018. Forensic Science International: Synergy, 3, 100138. https:\/\/doi.org\/10.1016\/j.fsisyn.2021.100138","journal-title":"Forensic Science International: Synergy"},{"key":"784_CR4","unstructured":"British Columbia Coroners Service. (2022). Illicit drug toxicity type of drug data (data to March 31, 2022). https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/statistical\/illicit-drug-type.pdf. Accessed 26 May 2022"},{"key":"784_CR5","doi-asserted-by":"publisher","first-page":"108609","DOI":"10.1016\/j.drugalcdep.2021.108609","volume":"221","author":"GA Bushnell","year":"2021","unstructured":"Bushnell, G. A., Olfson, M., & Martins, S. S. (2021). Sex differences in US emergency department non-fatal visits for benzodiazepine poisonings in adolescents and young adults. Drug and Alcohol Dependence, 221, 108609. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108609","journal-title":"Drug and Alcohol Dependence"},{"issue":"18","key":"784_CR6","doi-asserted-by":"publisher","first-page":"E659","DOI":"10.1503\/cmaj.170363","volume":"189","author":"JW Busse","year":"2017","unstructured":"Busse, J. W., Craigie, S., Juurlink, D. N., Buckley, D. N., Wang, L., Couban, R. J., Agoritsas, T., Akl, E. A., Carrasco-Labra, A., Cooper, L., Cull, C., da Costa, B. R., Frank, J. W., Grant, G., Iorio, A., Persaud, N., Stern, S., Tugwell, P., Vandvik, P. O., & Guyatt, G. H. (2017). Guideline for opioid therapy and chronic noncancer pain. CMAJ, 189(18), E659\u2013E666. https:\/\/doi.org\/10.1503\/cmaj.170363","journal-title":"CMAJ"},{"key":"784_CR7","unstructured":"Canadian Centre on Substance Use and Addiction. (2021). Risks and Harms Associated with the Nonmedical Use of Benzodiazepines in the Unregulated Drug Supply in Canada. https:\/\/www.ccsa.ca\/sites\/default\/files\/2021-12\/CCSA-CCENDU-Nonmedical-Use-Benzodiazepines-Unregulated-Drug-Supply-Bulletin-2021-en.pdf. Accessed 26 May 2022"},{"key":"784_CR8","unstructured":"Centre on Drug Policy Evaluation. (2022). What's in Toronto's drug supply? Centre on Drug Policy Evaluation. https:\/\/drugchecking.cdpe.org\/.\u00a0Accessed 26 May 2022"},{"issue":"15","key":"784_CR9","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","volume":"315","author":"D Dowell","year":"2016","unstructured":"Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC Guideline for Prescribing Opioids for Chronic Pain-United States, 2016. JAMA, 315(15), 1624\u20131645. https:\/\/doi.org\/10.1001\/jama.2016.1464","journal-title":"JAMA"},{"key":"784_CR10","unstructured":"Gomes, T., Murray, R., Kolla, G., Leece, P., Bansal, S., Besharah, J., Cahill, T., Campbell, T., Fritz, A., Munro, C., Toner, L., Watford, J., & on behalf of the Ontario Drug Policy Research Network Office of the Chief Coroner for Ontario and Ontario Agency for Health Protection and Promotion (Public Health Ontario). (2021). Changing Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic. O. D. P. R. Network. https:\/\/odprn.ca\/wp-content\/uploads\/2021\/05\/Changing-Circumstances-Surrounding-Opioid-Related-Deaths.pdf.\u00a0Accessed 26 May 2022"},{"issue":"4","key":"784_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jama.2020.22106","volume":"325","author":"ME Hirschtritt","year":"2021","unstructured":"Hirschtritt, M. E., Olfson, M., & Kroenke, K. (2021). Balancing the Risks and Benefits of Benzodiazepines. JAMA, 325(4), 347\u2013348. https:\/\/doi.org\/10.1001\/jama.2020.22106","journal-title":"JAMA"},{"key":"784_CR12","doi-asserted-by":"publisher","unstructured":"Huerta, C., Abbing-Karahagopian, V., Requena, G., Oliva, B., Alvarez, Y., Gardarsdottir, H., Miret, M., Schneider, C., Gil, M., Souverein, P. C., De Bruin, M. L., Slattery, J., De Groot, M. C., Hesse, U., Rottenkolber, M., Schmiedl, S., Montero, D., Bate, A., Ruigomez, A., . . . de Abajo, F. J. (2016). Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiol Drug Saf, 25 Suppl 1, 56\u201365. https:\/\/doi.org\/10.1002\/pds.3825","DOI":"10.1002\/pds.3825"},{"key":"784_CR13","unstructured":"ICES. (2023a). ICES Data. https:\/\/www.ices.on.ca\/Data-and-Privacy\/ICES-data. Accessed 8 Apr 2023"},{"key":"784_CR14","unstructured":"ICES. (2023b). Privacy at ICES. https:\/\/www.ices.on.ca\/Data-and-Privacy\/Privacy-at-ICES.\u00a0Accessed 8 Apr 2023"},{"key":"784_CR15","unstructured":"ICES. (2023c). Types of ICES data. https:\/\/www.ices.on.ca\/Data-and-Privacy\/ICES-data\/Types-of-ICES-Data.\u00a0Accessed 8 Apr 2023"},{"key":"784_CR16","unstructured":"Kang, M., Galuska, M. A., & Ghassemzadeh, S. (2022). Benzodiazepine Toxicity. In StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29489152. Accessed 7 Sept 2022"},{"issue":"11","key":"784_CR17","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1111\/ajt.16053","volume":"21","author":"S Liu","year":"2021","unstructured":"Liu, S., O\u2019Donnell, J., Matt Gladden, R., McGlone, L., & Chowdhury, F. (2021). Trends in nonfatal and fatal overdoses involving benzodiazepines\u201438 states and the District of Columbia, 2019\u20132020. American Journal of Transplantation, 21(11), 3794\u20133800.","journal-title":"American Journal of Transplantation"},{"key":"784_CR18","first-page":"2120","volume":"61","author":"L Longo","year":"2000","unstructured":"Longo, L., & Johnson, B. (2000). Benzodiazepines: Side effects, abuse risk, and alternatives: Addiction part 1. American Family Physician, 61, 2120\u20132130.","journal-title":"American Family Physician"},{"key":"784_CR19","doi-asserted-by":"crossref","unstructured":"Mamdani, M., Sykora, K., Li, P., Normand, S.-L. T., Streiner, D. L., Austin, P. C., Rochon, P. A., & Anderson, G. M. (2005). Reader\u2019s guide to critical appraisal of cohort studies: 2 Assessing Potential for Confounding. BMJ, 330(7497), 960\u2013962.","DOI":"10.1136\/bmj.330.7497.960"},{"key":"784_CR20","unstructured":"Marin, M. J., & van Wijk, X. M. R. (2019). The evolution of designer benzodiazepines: Challenges for detection and monitoring. Clinical Laboratory News. https:\/\/www.aacc.org\/cln\/articles\/2019\/november\/the-evolution-of-designer-benzodiazepines.\u00a0Accessed 25 May 2022"},{"issue":"4","key":"784_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.amepre.2019.11.017","volume":"58","author":"RN Moro","year":"2020","unstructured":"Moro, R. N., Geller, A. I., Weidle, N. J., Lind, J. N., Lovegrove, M. C., Rose, K. O., Goring, S. K., McAninch, J. K., Dowell, D., & Budnitz, D. S. (2020). Emergency Department Visits Attributed to Adverse Events Involving Benzodiazepines, 2016\u20132017. American Journal of Preventive Medicine, 58(4), 526\u2013535. https:\/\/doi.org\/10.1016\/j.amepre.2019.11.017","journal-title":"American Journal of Preventive Medicine"},{"key":"784_CR22","unstructured":"Ontario Drug Policy Research Network on behalf of the ODPRN Citizens\u2019 Panel. (2021). Characterizing Prescription Benzodiazepine Use Among Community-Dwelling Residents of Ontario, Canada. Ontario Drug Policy Research Network. https:\/\/odprn.ca\/wp-content\/uploads\/2021\/04\/Trends-and-Patterns-in-the-Use-of-Benzodiazepines-in-Ontario.pdf. Accessed 21 Jan 2022"},{"key":"784_CR23","unstructured":"Ontario Drug Policy Research Network, Office of the Chief Coroner for Ontario\/Ontario Forensic Pathology Service, Ontario Agency for Health Protection and Promotion (Public Health Ontario), & Centre on Drug Policy Evaluation. (2020). Preliminary Patterns in Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic. https:\/\/odprn.ca\/wp-content\/uploads\/2020\/11\/Opioid-Death-Report_FINAL-2020NOV09.pdf.\u00a0Accessed 26 May 2022"},{"issue":"8","key":"784_CR24","doi-asserted-by":"publisher","first-page":"e1002635","DOI":"10.1371\/journal.pmed.1002635","volume":"15","author":"A Sidorchuk","year":"2018","unstructured":"Sidorchuk, A., Isomura, K., Molero, Y., Hellner, C., Lichtenstein, P., Chang, Z., Franck, J., Fernandez de la Cruz, L., & Mataix-Cols, D. (2018). Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: A total population register-linkage study. PLoS Med, 15(8), e1002635. https:\/\/doi.org\/10.1371\/journal.pmed.1002635","journal-title":"PLoS Med"},{"key":"784_CR25","unstructured":"Statistics Canada. (2019). Postal CodeOM Conversion File Plus (PCCF+) Version 7C, Reference Guide. https:\/\/mdl.library.utoronto.ca\/sites\/default\/public\/mdldata\/open\/canada\/national\/statcan\/postalcodes\/pccfplus\/2016\/7c_2019nov\/Userguide-EN-22122020.pdf. Accessed 8 Apr 2023"},{"issue":"13","key":"784_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.15585\/mmwr.mm6913a3","volume":"69","author":"AM Vivolo-Kantor","year":"2020","unstructured":"Vivolo-Kantor, A. M., Hoots, B. E., Scholl, L., Pickens, C., Roehler, D. R., Board, A., Mustaquim, D., Smith, H. T., Snodgrass, S., & Liu, S. (2020). Nonfatal Drug Overdoses Treated in Emergency Departments - United States, 2016\u20132017. MMWR. Morbidity and Mortality Weekly Report, 69(13), 371\u2013376. https:\/\/doi.org\/10.15585\/mmwr.mm6913a3","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"4","key":"784_CR27","doi-asserted-by":"publisher","first-page":"E678","DOI":"10.9778\/cmajo.20180121","volume":"6","author":"DL Weir","year":"2018","unstructured":"Weir, D. L., Samanani, S., Gilani, F., Jess, E., & Eurich, D. T. (2018). Benzodiazepine receptor agonist dispensations in Alberta: A population-based descriptive study. CMAJ Open, 6(4), E678\u2013E684. https:\/\/doi.org\/10.9778\/cmajo.20180121","journal-title":"CMAJ Open"}],"container-title":["Canadian Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-023-00784-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.17269\/s41997-023-00784-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-023-00784-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T17:03:15Z","timestamp":1700499795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.17269\/s41997-023-00784-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["784"],"URL":"https:\/\/doi.org\/10.17269\/s41997-023-00784-3","relation":{},"ISSN":["0008-4263","1920-7476"],"issn-type":[{"value":"0008-4263","type":"print"},{"value":"1920-7476","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"7 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of the data in this project is authorized under Sect.\u00a045 of Ontario\u2019s Personal Health Information Protection Act and does not require review by a Research Ethics Board. The use of the data in this project is also approved by ICES\u2019 Privacy and Legal Office.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"ICES is a prescribed entity under Ontario\u2019s Personal Health Information Protection Act (PHIPA). Section\u00a045 of PHIPA authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}